In recent years, intensive molecular biological analyses of medulloblastomas have led to their categorization into distinct subgroups that differ in cytogenetics, mutational spectra, and gene expression signatures, as well as in clinical phenotypes and outcomes. The current consensus is that medulloblastomas consist of four core subgroups : WNT, SHH, Group 3, and Group 4. The biological and clinical properties of these molecular subgroups are being elucidated. The characterization and standardization of these subgroups, and their integration into the next World Health Organization (WHO) classification of central nervous system tumors are currently being discussed. The continued molecular and genetic characterization of medulloblastoma using the four-subgroup system will increase our understanding of the biology of these tumors (both primary and metastatic tumors) and lead to improved diagnosis and risk stratification systems. Furthermore, this research will contribute to the development of novel therapeutics (e. g. SMO inhibitors) and strategies.
On the other hand, domestic research in this field has lagged. A Japanese system for the molecular diagnosis of medulloblastomas is needed, with consensus for new molecular subgroups and clinical trials based on these groups. To this end, we have formed the Japanese Pediatric Molecular Neuro-oncology Group (JPMNG) as a joint research project between the Japanese Society for Pediatric Neurosurgery (JSPN) and the Japan Society for Neuro-Oncology (JSNO), and have begun a clinical research project to establish a Japanese molecular diagnosis system for pediatric brain tumors, initially targeting medulloblastoma and ependymoma, with support from the Hospital for Sick Children (Toronto) and other international collaborators. In the JPMNG project, medulloblastoma or ependymoma tissue samples are being collected, and methods will be developed to classify them into molecular subgroups reliably and reproducibly, according to the results from gene expression analysis (using the NanoString nCounter system), immunohistochemistry, DNA sequencing by the Sanger method or next-generation sequencers, fluorescence in situ hybridization (FISH), and DNA methylation analysis.
The molecular and genetic diagnosis of medulloblastoma is critically related to tumor classification, clinical risk stratification, and tumor biology analysis. We expect that the JPMNG project will improve the molecular diagnosis of medulloblastoma, leading to more appropriate treatments and better clinical outcomes in Japan.
View full abstract